Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PiB) binds with high affinity to beta-pleated sheet aggregates of the amyloid-beta (Abeta) peptide in vitro. The in vivo retention of PiB in brains of people with Alzheimer's disease shows a regional distribution that is very similar to distribution of Abeta deposits observed post-mortem. However, the basis for regional variations in PiB binding in vivo, and the extent to which it binds to different types of Abeta-containing plaques and tau-containing neurofibrillary tangles (NFT), has not been thoroughly investigated. The present study examined 28 clinically diagnosed and autopsy-confirmed Alzheimer's disease subjects, including one Alzheimer's disease subject who had undergone PiB-PET imaging 10 months prior to death, to evaluate region- and substrate-specific binding of the highly fluorescent PiB derivative 6-CN-PiB. These data were then correlated with region-matched Abeta plaque load and peptide levels, [(3)H]PiB binding in vitro, and in vivo PET retention levels. We found that in Alzheimer's disease brain tissue sections, the preponderance of 6-CN-PiB binding is in plaques immunoreactive to either Abeta42 or Abeta40, and to vascular Abeta deposits. 6-CN-PiB labelling was most robust in compact/cored plaques in the prefrontal and temporal cortices. While diffuse plaques, including those in caudate nucleus and presubiculum, were less prominently labelled, amorphous Abeta plaques in the cerebellum were not detectable with 6-CN-PiB. Only a small subset of NFT were 6-CN-PiB positive; these resembled extracellular 'ghost' NFT. In Alzheimer's disease brain tissue homogenates, there was a direct correlation between [(3)H]PiB binding and insoluble Abeta peptide levels. In the Alzheimer's disease subject who underwent PiB-PET prior to death, in vivo PiB retention levels correlated directly with region-matched post-mortem measures of [(3)H]PiB binding, insoluble Abeta peptide levels, 6-CN-PiB- and Abeta plaque load, but not with measures of NFT. These results demonstrate, in a typical Alzheimer's disease brain, that PiB binding is highly selective for insoluble (fibrillar) Abeta deposits, and not for neurofibrillary pathology. The strong direct correlation of in vivo PiB retention with region-matched quantitative analyses of Abeta plaques in the same subject supports the validity of PiB-PET imaging as a method for in vivo evaluation of Abeta plaque burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 Correlations of the in vivo PiB DVR values from the 19 VOIs (six of the 25 VOIs had <70% tissue and were not included in the analysis, see Methods section) on the PET scan with post-mortem quantifications of 6-CN-PiB (A) or Aβ (B) plaque load, neurofibrillary load (C) and [3H]PiB binding (D) in the corresponding 19 tissue cubes from the formalin fixed left hemisphere. In vivo PiB-PET retention (DVR) levels correlate directly with regional post-mortem quantitations of 6-CN-PiB (A) and 6E10 (B) plaque loads as well as in vitro PiB binding (D), but not with AT8 neurofibrillary load (C) in formalin-fixed tissue from the left hemisphere. In fresh-frozen tissue from the right hemisphere of the same Alzheimer's disease subject, there is a significant correlation of both in vitro PiB binding (E) and total insoluble Aβ (Aβ1–40 + Aβ1–42) peptide levels (F) with in vivo PiB-PET retention (DVR) levels.](https://figures.cochat.ai/paper-figures/e33db6b5b74a421cb6ab860a36a812a8/post-mortem-correlates-of-in-vivo-pib-pet-amyloid-imaging-in-a-typical-case-of-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in accordance with the relative resistance of this region to pathology in mouse AD models and AD patients26”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent amyloid imaging techniques have proved an association with Alzheimer disease pathology235 and may prove useful for evaluating the independent and combined effects of vascular and Alzheimer disease brain injury on cognitive changes during normal aging in the future.”
The cited source says what the claim attributes to it.
In the citing paper
“Imaging-to-autopsy comparison studies have established that amyloid positron emission tomography (PET) is a valid in vivo surrogate for Aβ deposits (in brain parenchyma/vessel walls) [17–24].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“the [11C]-benzothiazole radiotracer, Pittsburgh Compound B (PIB), as well as other tracers, can bind to fibrillar Aβ plaques, allowing for visualization of brain amyloid in individuals during positron emission tomography (PET) (23-25).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“In this case, the final neuropathological diagnosis by CERAD criteria (Mirra et al., 1991) was ‘definite Alzheimer’s disease’, and the Braak stage (Braak and Braak, 1991b) was V/VI.”
BackgroundResultMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 7×
“…Alzheimer’s disease patients have 2- to 3-fold greater PiB retention on PET scans in brain areas known to have high amounts of fibrillar (i.e. Congo red and thioflavin-S labelled) Ab plaques in Alzheimer’s disease, such as frontal cortex and temporal lobe (Klunk et al., 2004; Price et al., 2005).”
BackgroundInfluentialSelf-citationGauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Simplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,021 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
MethodIwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · cited 1×
“Ab42-containing plaques and Ab42 peptide levels are much more abundant in Alzheimer’s disease brain (Iwatsubo et al., 1994; Naslund et al., 2000), and therefore likely drive the correlation between PiB and total Ab peptide (Ab42 and Ab40 combined) levels as determined in our ELISA assays.”
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
MethodCorrelation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268 · cited 1×
“Ab42-containing plaques and Ab42 peptide levels are much more abundant in Alzheimer’s disease brain (Iwatsubo et al., 1994; Naslund et al., 2000), and therefore likely drive the correlation between PiB and total Ab peptide (Ab42 and Ab40 combined) levels as determined in our ELISA assays.”
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Self-citationMasters, C. L., Multhaup, G., Simms, G., Pottgiesser, J., Martins, R. N., & Beyreuther, K. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb04000.x · Cited by 1,042 · cited 2×
“Since select NFT, and particularly extracellular NFT, contain epitopes recognized by Ab antibodies (Masters et al., 1985; Grundke-Iqbal et al., 1989; Hyman et al., 1989; Spillantini et al., 1990; Tabaton et al., 1991; Perry et al., 1993), we must also consider the possibility that the NFT labelled by 6-CN-PiB and BTA-…”
BackgroundSynthesis and Evaluation of 11C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents
Mathis, C. A., Wang, Y., Holt, D. P., Huang, G.-F., Debnath, M. L., & Klunk, W. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030026b · Cited by 979
Self-citationMintun, M. A., Raichle, M. E., Kilbourn, M. R., Wooten, G. F., & Welch, M. J. (1984) · Annals of Neurology · doi:10.1002/ana.410150302 · Cited by 955 · cited 1×
“The DVR is a unitless value related directly to the free binding-site pool (Bmax) and the ligand dissociation constant (Kd) (Mintun et al., 1984), and is a measure of region-specific PiB retention (Lopresti et al., 2005).”
BackgroundPET of Brain Amyloid and Tau in Mild Cognitive Impairment
Small, G. W., Kepe, V., Ercoli, L. M., Siddarth, P., Bookheimer, S. Y., Miller, K. J., Lavretsky, H., Burggren, A. C., Cole, G. M., Vinters, H. V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054625 · Cited by 738 · cited 2×
“Positron emission tomography (PET) imaging of amyloid deposits (Klunk et al., 2004; Verhoeff et al., 2004; Small et al., 2006) employs blood–brain barrier penetrant amyloid-binding compounds such as the thioflavin-T derivative Pittsburgh Compound-B (PiB) (Klunk et al., 2001, 2004; Mathis et al.,…”
BackgroundPET imaging of amyloid deposition in patients with mild cognitive impairment
Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., Ringheim, A., Långström, B., & Nordberg, A. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.029 · Cited by 728 · cited 2×
“PiB-PET is able to track Ab deposition across the spectrum of normal aging to advanced Alzheimer’s disease (Forsberg et al., 2007; Kemppainen et al., 2007; Rowe et al., 2007), and further histological studies will need to be performed to assess the relative contributions of different plaque types…”
BackgroundKinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B
Price, J. C., Klunk, W. E., Lopresti, B. J., Lu, X., Hoge, J. A., Ziolko, S. K., Holt, D. P., Meltzer, C. C., DeKosky, S. T., & Mathis, C. A. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600146 · Cited by 720 · cited 3×
“…Alzheimer’s disease patients have 2- to 3-fold greater PiB retention on PET scans in brain areas known to have high amounts of fibrillar (i.e. Congo red and thioflavin-S labelled) Ab plaques in Alzheimer’s disease, such as frontal cortex and temporal lobe (Klunk et al., 2004; Price et al., 2005).”
BackgroundMethodSelf-citationConsensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
(1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 666
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease
Engler, H., Forsberg, A., Almkvist, O., Blomquist, G., Larsson, E., Savitcheva, I., Wall, A., Ringheim, A., Langstrom, B., & Nordberg, A. (2006) · Brain · doi:10.1093/brain/awl178 · Cited by 617 · cited 1×
“Although the PiBPET study and autopsy were separated by 10 months, Engler et al. (2006) have shown that PiB-PET DVR values do not change appreciably over 2 years in patients with Alzheimer’s disease.”
BackgroundKamal, A., Almenar-Queralt, A., LeBlanc, J. F., Roberts, E. A., & Goldstein, L. S. B. (2001) · Nature · doi:10.1038/414643a · Cited by 583 · cited 1×
“, 1992) Ab40 (rabbit) Ala-40; Ab1^40 1:1000 Chemicon (Kamal et al., 2001) Ab42 (rabbit) Ala-42; Ab1^42 1:1000 Chemicon (Kamal et al.”
Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease
Mayeux, R., Saunders, A. M., Shea, S., Mirra, S., Evans, D., Roses, A. D., Hyman, B. T., Crain, B., Tang, M.-X., & Phelps, C. H. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802193380804 · Cited by 547
Lopresti, B. J., Klunk, W. E., Mathis, C. A., Hoge, J. A., Ziolko, S. K., Lu, X., MELTZER, C. C., Schimmel, K., Tsopelas, N. D., DeKosky, S. T., et al. (2005) · PubMed · Cited by 543
Self-citationImaging of amyloid burden and distribution in cerebral amyloid angiopathy
Johnson, K. A., Gregas, M., Becker, J. A., Kinnecom, C., Salat, D. H., Moran, E. K., Smith, E. E., Rosand, J., Rentz, D. M., Klunk, W. E., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21164 · Cited by 495 · cited 4×
“…that vascular amyloidosis can contribute significantly to PiB-PET signal (Bacskai et al., 2007), as did a study of cerebral amyloid angiopathy (CAA) (Johnson et al., 2007), while Lewy bodies themselves contributed little if at all to overall PiB-PET signal (Fodero-Tavoletti et al., 2007).”
BackgroundInfluentialSelf-citationFormic acid pretreatment enhances immunostaining of cerebral and systemic amyloids.
Kitamoto, T., Ogomori, K., Tateishi, J., & Prusiner, S. B. (1987) · PubMed · Cited by 472
Klunk, W. E., Wang, Y., Huang, G.-F., Debnath, M. L., Holt, D. P., & Mathis, C. A. (2001) · Life Sciences · doi:10.1016/s0024-3205(01)01232-2 · Cited by 457 · cited 2×
“…tomography (PET) imaging of amyloid deposits (Klunk et al., 2004; Verhoeff et al., 2004; Small et al., 2006) employs blood–brain barrier penetrant amyloid-binding compounds such as the thioflavin-T derivative Pittsburgh Compound-B (PiB) (Klunk et al., 2001, 2004; Mathis et al., 2002, 2004, 2005).”
BackgroundMethodSelf-citationMathis, C. A., Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Frosch, M. P., Hyman, B. T., Holt, D. P., Wang, Y., Huang, G.-F., Debnath, M. L., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00734-x · Cited by 403 · cited 1×
“…tomography (PET) imaging of amyloid deposits (Klunk et al., 2004; Verhoeff et al., 2004; Small et al., 2006) employs blood–brain barrier penetrant amyloid-binding compounds such as the thioflavin-T derivative Pittsburgh Compound-B (PiB) (Klunk et al., 2001, 2004; Mathis et al., 2002, 2004, 2005).”
BackgroundSelf-citationKlunk, W. E., Lopresti, B. J., Ikonomovic, M. D., Lefterov, I. M., Koldamova, R. P., Abrahamson, E. E., Debnath, M. L., Holt, D. P., Huang, G.-F., Shao, L., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2990-05.2005 · Cited by 377 · cited 3×
“The low-affinity components had Kd values of 70–145 nM and thus represent binding that would not be relevant in vivo where [C]PiB concentrations are on the order of 1 nM or less (Klunk et al., 2005).”
BackgroundResultInfluentialSelf-citationMercken, M., Vandermeeren, M., Lübke, U., Six, J., Boons, J., Van de Voorde, A., Martin, J.-J., & Gheuens, J. (1992) · Acta Neuropathologica · doi:10.1007/bf00227819 · Cited by 355 · cited 1×
“, 1990) AT8 (mouse) Ser-202 (P) of tau 1:10,000 Signet (Mercken et al., 1992) Ab40 (rabbit) Ala-40; Ab1^40 1:1000 Chemicon (Kamal et al.”
Molecular Imaging With Pittsburgh Compound B Confirmed at Autopsy: A Case Report
Bacskai, B. J., Frosch, M. P., Freeman, S. H., Raymond, S. B., Augustinack, J. C., Johnson, K. A., Irizarry, M. C., Klunk, W. E., Mathis, C. A., DeKosky, S. T., et al. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.431 · Cited by 341 · cited 11×
“Keywords: Pittsburgh Compound-B; PiB; amyloid imaging; plaques; PET imaging Abbreviations: Ab=amyloid-b peptide; AC-PC=the plane of anterior comissure-posterior comissure; BA=Brodmann area; CAA=cerebral amyloid angiopathy; DVR=Logan distribution volume ratio; ELISA=enzyme linked immunoadsorbant assay; ERC=entorhinal c…”
BackgroundInfluentialSelf-citationIn-Vivo Imaging of Alzheimer Disease -Amyloid With [11C]SB-13 PET
Verhoeff, N. P. L. G. (2004) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.12.6.584 · Cited by 317 · cited 1×
“Positron emission tomography (PET) imaging of amyloid deposits (Klunk et al., 2004; Verhoeff et al., 2004; Small et al., 2006) employs blood–brain barrier penetrant amyloid-binding compounds such as the thioflavin-T derivative Pittsburgh Compound-B (PiB) (Klunk et al.”
BackgroundKlunk, W. E., Wang, Y., Huang, G.-F., Debnath, M. L., Holt, D. P., Shao, L., Hamilton, R. L., Ikonomovic, M. D., DeKosky, S. T., & Mathis, C. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02086.2003 · Cited by 309 · cited 3×
“In agreement with these observations in vivo, studies of post-mortem Alzheimer’s disease brain homogenates show that PiB binds preferentially to Ab fibrils (Klunk et al., 2003a), suggesting that PiB imaging could serve as a tool for monitoring changes in Ab pathology in Alzheimer’s disease.”
MethodResultSelf-citationPET amyloid ligand [ 11 C]PIB uptake is increased in mild cognitive impairment
Kemppainen, N. M., Aalto, S., Wilson, I. A., Någren, K., Helin, S., Brück, A., Oikonen, V., Kailajärvi, M., Scheinin, M., Viitanen, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000260969.94695.56 · Cited by 308 · cited 2×
“PiB-PET is able to track Ab deposition across the spectrum of normal aging to advanced Alzheimer’s disease (Forsberg et al., 2007; Kemppainen et al., 2007; Rowe et al., 2007), and further histological studies will need to be performed to assess the relative contributions of different plaque types…”
BackgroundPIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis
Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G. (2007) · Brain · doi:10.1093/brain/awm191 · Cited by 302 · cited 4×
“study (Lockhart et al., 2007), some N-terminus Ab truncated diffuse Ab plaques in the ERC could have gone undetected by the N-terminus Ab IHC and thioflavin-S histochemistry.”
BackgroundInfluentialMaeda, J., Ji, B., Irie, T., Tomiyama, T., Maruyama, M., Okauchi, T., Staufenbiel, M., Iwata, N., Ono, M., Saido, T. C., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0673-07.2007 · Cited by 300 · cited 2×
“…PiB binding, but a recent paper examining PiB binding to brain tissue from transgenic mouse models of amyloid deposition suggested that the form of Ab starting with cyclized glutamate in the 3-position [i.e. pyroglutamate or N3(pE) form] is a major contributor to PiB binding (Maeda et al., 2007).”
BackgroundThies, E., & Mandelkow, E.-M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4674-06.2007 · Cited by 293
Aβ Species Removal After Aβ 42 Immunization
Nicoll, J. A. R., Barton, E., Boche, D., Neal, J. W., Ferrer, I., Thompson, P., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., et al. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000240466.10758.ce · Cited by 265
Comparative evaluation of MR-based partial-volume correction schemes for PET.
MELTZER, C. C., Kinahan, P. E., Greer, P. J., Nichols, T. E., Comtat, C., Cantwell, M. N., Lin, M., & Price, J. C. (1999) · PubMed · Cited by 254
Self-citationImaging β-Amyloid Plaques and Neurofibrillary Tangles in the Aging Human Brain
Mathis, C., Wang, Y., & Klunk, W. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384772 · Cited by 243 · cited 1×
“…tomography (PET) imaging of amyloid deposits (Klunk et al., 2004; Verhoeff et al., 2004; Small et al., 2006) employs blood–brain barrier penetrant amyloid-binding compounds such as the thioflavin-T derivative Pittsburgh Compound-B (PiB) (Klunk et al., 2001, 2004; Mathis et al., 2002, 2004, 2005).”
BackgroundSelf-citationThe Role of Biomarkers in Clinical Trials for Alzheimer Disease
Thal, L. J., Kantarci, K., Reiman, E. M., Klunk, W. E., Weiner, M. W., Zetterberg, H., Galasko, D., Praticò, D., Griffin, S., Schenk, D., et al. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000191420.61260.a8 · Cited by 232 · cited 1×
“Thus sensitive in vivo markers of Alzheimer’s disease brain lesions are needed (Consensus, 1998; Klunk, 1998; Growdon, 1999; Morris et al., 2005; Thal et al., 2006).”
BackgroundSelf-citationHarigaya, Y., Saido, T. C., Eckman, C. B., Prada, C.-M., Shoji, M., & Younkin, S. G. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3490 · Cited by 202 · cited 1×
“This is of interest given the previously reported findings that the N3(pE) form of Ab comprises 25–50% of total Ab (Harigaya et al., 2000; Russo et al., 2002).”
BackgroundRusso, C., Violani, E., Salis, S., Venezia, V., Dolcini, V., Damonte, G., Benatti, U., D'Arrigo, C., Patrone, E., Carlo, P., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01107.x · Cited by 198 · cited 1×
“This is of interest given the previously reported findings that the N3(pE) form of Ab comprises 25–50% of total Ab (Harigaya et al., 2000; Russo et al., 2002).”
BackgroundResearch evaluation and diagnosis of possible Alzheimer’s disease over the last two decades: II
Lopez, O. L., Becker, J. T., Klunk, W., Saxton, J., Hamilton, R. L., Kaufer, D. I., Sweet, R. A., Cidis Meltzer, C., Wisniewski, S., Kamboh, M. I., et al. (2000) · Neurology · doi:10.1212/wnl.55.12.1863 · Cited by 185 · cited 2×
“Clinically symptomatic Alzheimer’s disease can be diagnosed with high accuracy at academic centres (Lopez et al., 2000a, b), but diagnosis in the community is less accurate (Pearl, 1997).”
BackgroundSelf-citationAmyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease.
Grundke, I., Iqbal, K., George, L., Tung, Y. C., Kim, K. S., & Wisniewski, H. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.8.2853 · Cited by 171 · cited 3×
“…also consider the possibility that the NFT labelled by 6-CN-PiB and BTA-1 represent NFT-associated Ab peptides that fibrilized once Downloaded from https://academic.oup.com/brain/article-abstract/131/6/1630/316007 by guest on 29 July 2018 the NFT became extracellular (Grundke-Iqbal et al., 1989).”
BackgroundResearch evaluation and diagnosis of probable Alzheimer’s disease over the last two decades: I
López, O. L., Becker, J. T., Klunk, W. E., Saxton, J. A., Hamilton, R. L., Kaufer, D., Sweet, R. A., MELTZER, C. C., Wisniewski, S. R., Kamboh, M. I., et al. (2000) · Neurology · doi:10.1212/wnl.55.12.1854 · Cited by 171 · cited 1×
“Clinically symptomatic Alzheimer’s disease can be diagnosed with high accuracy at academic centres (Lopez et al., 2000a, b), but diagnosis in the community is less accurate (Pearl, 1997).”
BackgroundSelf-citationIn Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies
Fodero-Tavoletti, M. T., Smith, D. P., McLean, C. A., Adlard, P. A., Barnham, K. J., Foster, L. E., Leone, L., Perez, K., Cortés, M., Culvenor, J. G., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0630-07.2007 · Cited by 159 · cited 1×
“Although the PiBPET study and autopsy were separated by 10 months, Engler et al. (2006) have shown that PiB-PET DVR values do not change appreciably over 2 years in patients with Alzheimer’s disease.”
BackgroundLalowski, M. M., Golabek, A. A., Lemere, C. A., Selkoe, D. J., Wísniewski, H. M., Beavis, R. C., Frangione, B., & Wısnıewskı, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.52.33623 · Cited by 153 · cited 1×
“The binding of PiB to diffuse plaques in the striatum and other regions examined, but not in the cerebellum, is likely due to the unique secondary structure and amino acid composition of cerebellar diffuse Ab aggregates (Lalowski et al., 1996).”
BackgroundDeKosky, S. T., Abrahamson, E. E., Ciallella, J. R., Paljug, W. R., Wisniewski, S. R., Clark, R. S. B., & Ikonomovic, M. D. (2007) · Archives of Neurology · doi:10.1001/archneur.64.4.541 · Cited by 152 · cited 1×
“Ab enzyme linked immunoadsorbant assay (ELISA) Ab1–40 and Ab1–42 peptides were quantified in both soluble (diethylamine, DEA) and insoluble (FA extracted) Ab fractions following a published protocol (DeKosky et al., 2007).”
MethodSelf-citationMena, R., Edwards, P. C., Harrington, C. R., Mukaetova‐Ladinska, E. B., & Wischik, C. M. (1996) · Acta Neuropathologica · doi:10.1007/s004010050477 · Cited by 140 · cited 1×
“Alternatively, extracellular proteolysis of tau in extracellular NFT may expose the protease-resistant core of PHF, or change its structure (Mena et al., 1995, 1996) making it accessible to PiB.”
BackgroundGuntern, R., Bouras, C., Hof, P. R., & Vallet, P. G. (1992) · Cellular and Molecular Life Sciences · doi:10.1007/bf01923594 · Cited by 138 · cited 3×
“6-CN-PiB, X-34 and Thio-S histofluorescence Tissue sections were slide mounted and processed for attenuation of lipofuscin autofluorescence (Guntern et al., 1992).”
MethodInfluentialHyman, B. T., Tanzi, R. E., Marzloff, K., Barbour, R., & Schenk, D. (1992) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199201000-00009 · Cited by 135 · cited 1×
“, 2007) 10D5 (mouse) Ab aa3^6 1:3000 Elan (Hyman et al., 1992)”
Biomarkers of Alzheimer Disease
Growdon, J. H. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.281 · Cited by 113
Tabaton, M., Cammarata, S., Mancardi, G., Manetto, V., AUTILIO‐GAMBETTI, L., Perry, G. L., & Gambetti, P. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.6.2098 · Cited by 99 · cited 2×
“Since select NFT, and particularly extracellular NFT, contain epitopes recognized by Ab antibodies (Masters et al., 1985; Grundke-Iqbal et al., 1989; Hyman et al., 1989; Spillantini et al., 1990; Tabaton et al., 1991; Perry et al., 1993), we must also consider the possibility that the NFT labelled by 6-CN-PiB and BTA-…”
BackgroundImaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography
Klunk, W. E., Engler, H., Nordberg, A., Bacskai, B. J., Wang, Y., Price, J. C., Bergström, M., Hyman, B. T., Långström, B., & Mathis, C. A. (2003) · Neuroimaging Clinics of North America · doi:10.1016/s1052-5149(03)00092-3 · Cited by 96 · cited 4×
“Unlabelled PiB was dissolved in DMSO at 400 mM (to yield 51% DMSO in the final assay).”
MethodResultInfluentialSelf-citationVerga, L., Frangione, B., Tagliavini, F., Giaccone, G., Migheli, A., & Bugiani, O. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90636-8 · Cited by 87 · cited 1×
“Furthermore, unlike the occasional small compact plaques that were 6-CN-PiB positive, cerebellar diffuse plaques contain few amyloid fibrils characteristic of plaque cores (Verga et al., 1989).”
BackgroundMonitoring pathological assembly of tau and ?-amyloid proteins in Alzheimer's disease
Mena, R., Edwards, P., P�rez-Olvera, O., & Wischik, C. M. (1994) · Acta Neuropathologica · doi:10.1007/bf00294259 · Cited by 85
Biological Markers of Alzheimer’s Disease
Klunk, W. E. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00013-x · Cited by 81
Self-citationA4 amyloid protein immunoreactivity is present in Alzheimer's disease neurofibrillary tangles
Hyman, B. T., Hoesen, G. W. V., Beyreuther, K. T., & Masters, C. L. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90559-4 · Cited by 74 · cited 2×
“Since select NFT, and particularly extracellular NFT, contain epitopes recognized by Ab antibodies (Masters et al., 1985; Grundke-Iqbal et al., 1989; Hyman et al., 1989; Spillantini et al., 1990; Tabaton et al., 1991; Perry et al., 1993), we must also consider the possibility that the NFT labelled by 6-CN-PiB and BTA-…”
BackgroundImaging Technology for Neurodegenerative Diseases
Mathis, C. A., Klunk, W. E., Price, J. C., & DeKosky, S. T. (2005) · Archives of Neurology · doi:10.1001/archneur.62.2.196 · Cited by 68 · cited 1×
“…tomography (PET) imaging of amyloid deposits (Klunk et al., 2004; Verhoeff et al., 2004; Small et al., 2006) employs blood–brain barrier penetrant amyloid-binding compounds such as the thioflavin-T derivative Pittsburgh Compound-B (PiB) (Klunk et al., 2001, 2004; Mathis et al., 2002, 2004, 2005).”
BackgroundSelf-citationX‐34 Labeling of Abnormal Protein Aggregates During the Progression of Alzheimer's Disease
Ikonomović, M. D., Abrahamson, E. E., Isanski, B. A., Debnath, M. L., Mathis, C. A., DeKosky, S. T., & Klunk, W. E. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(06)12009-1 · Cited by 62 · cited 3×
“The overall X-34 labelling load, which reveals all b-sheet deposits including Ab plaques and neurofibrillary pathology (NFT, DN and NT) (Ikonomovic et al., 2006), did not correspond as well to 6-CN-PiB labelling as did 6E10 IHC for Ab alone.”
BackgroundMethodSelf-citationSpillantini, M. G., Goedert, M., Jakes, R., & Klug, A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.10.3952 · Cited by 62
Perry, G. L., Richey, P. L., Siedlak, S. L., Smith, M. A., Mulvihill, P., DeWitt, D. A., Barnett, J. L., Greenberg, B. D., & Kalaria, R. N. (1993) · PubMed · Cited by 49
Diagnosis of Alzheimer's Disease in a Community Hospital-Based Brain Bank Program
Pearl, G. (1997) · Southern medical journal (Birmingham, Ala. Print) · doi:10.1097/00007611-199707000-00013 · Cited by 28 · cited 2×
“…in vivo PiB-PETamyloid imaging in a typical case of Alzheimer’s disease Milos D. Ikonomovic,1,2 William E. Klunk,2 Eric E. Abrahamson,1 Chester A. Mathis,3 Julie C. Price,3 Nicholas D.Tsopelas,2 Brian J. Lopresti,3 Scott Ziolko,3 Wenzhu Bi,3 William R. Paljug,1Manik L. Debnath,2 Caroline E.…”
BackgroundRole of biomarkers in studies of presymptomatic Alzheimer's disease
Morris, J. C., Kimberly, A., Quaid, K. A., Holtzman, D. M., Kantarci, K., Kaye, J. A., Reiman, E. M., Klunk, W. E., & Siemers, E. (2005) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2005.09.013 · Cited by 26 · cited 1×
“Thus sensitive in vivo markers of Alzheimer’s disease brain lesions are needed (Consensus, 1998; Klunk, 1998; Growdon, 1999; Morris et al., 2005; Thal et al., 2006).”
Self-citationEditorial Board, Burns, A. S., Challis, D., Dennis, J., Hughes, J., Burns, A. S., Byrne, E. J., Findlay, D., & Dementia, V. (2013) · Routledge eBooks · doi:10.4324/9780203120804-11 · Cited by 26
Research works printed but not linked: 2
- Braak, 1991, Neuropathological staging of Alzheimer's disease, Acta Neuropath, 82, 239, 10.1007/BF00308809 · DOI · Paper page
- Kim, 1990, Detection and quantification of β-peptide with two monoclonal antibodies, Neurosci Res Commun, 7, 113
Cited by
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
“PiB specifically binds to fibrillar A β , and not to soluble A β or to diffuse plaques.26 35 The evidence therefore strongly supports the notion that both amyloid imaging and low CSF A β 42 are valid biomarkers of brain A β -plaque load.”
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citation
Metadata
- Authors
- Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., Debnath, M. L., Hope, C. E., Isanski, B. A., Hamilton, R. L., & DeKosky, S. T.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- DeKosky, Steven T.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-12
- Volume
- 131
- Issue
- 6
- Pages
- 1630-1645
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC2408940
- OpenAlex
- W2156981442
- Cited by
- 933
- References
- 66
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 29 · 2023: 25 · 2022: 33 · 2021: 42 · 2020: 44 · 2019: 56 · 2018: 51 · 2017: 46 · 2016: 58 · 2015: 57 · 2014: 82 · 2013: 81 · 2012: 79
- FWCI
- 47.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, public-domain)
- Funders
- U.S. Department of Energy (FG02-03ER63590, DE-FD02-03 ER63590, ER63590, DE-FD02-03)
- Alzheimer's Association (AG14449, TLL-01-3381)
- University of Pittsburgh (AG05133)
- National Institute for Health and Care Research
- National Institutes of Health (AG05133, AG025204, AG14449, AG025516)
- National Institute on Aging (AG 05-133, R01AG018402, P01AG025204, RF1AG025516, P50AG005133, P01AG014449, R01AG020226, AG025516, K02AG001039, P01 AG14449, P50-AG-05133, R37AG025516, R01AG025516)
- National Institute of Mental Health (R01MH070729, K01MH001976)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, amyloid plaques, Pittsburgh compound B, neurofibrillary tangles, tau protein, postmortem brain, amyloid-beta 42, Aβ40, vascular amyloid deposits, prefrontal cortex, temporal cortex, cerebellum
- MeSH terms
- Alzheimer Disease, Aniline Compounds, Autopsy, Brain, Carbon Radioisotopes, Enzyme-Linked Immunosorbent Assay, Female, Humans, Image Interpretation, Computer-Assisted, Immunohistochemistry, Magnetic Resonance Imaging, Middle Aged, Thiazoles, Reproducibility of Results, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.